Deciphering essential cistromes using genome-wide CRISPR screens.

Although millions of transcription factor binding sites, or cistromes, have been identified across the human genome, defining which of these sites is functional in a given condition remains challenging. Using CRISPR/Cas9 knockout screens and gene essentiality or fitness as the readout, we systematically investigated the essentiality of over 10,000 FOXA1 and CTCF binding sites in breast and prostate cancer cells. We found that essential FOXA1 binding sites act as enhancers to orchestrate the expression of nearby essential genes through the binding of lineage-specific transcription factors. In contrast, CRISPR screens of the CTCF cistrome revealed 2 classes of essential binding sites. The first class of essential CTCF binding sites act like FOXA1 sites as enhancers to regulate the expression of nearby essential genes, while a second class of essential CTCF binding sites was identified at topologically associated domain (TAD) boundaries and display distinct characteristics. Using regression methods trained on our screening data and public epigenetic profiles, we developed a model to predict essential cis -elements with high accuracy. The model for FOXA1 essentiality correctly predicts noncoding variants associated with cancer risk and progression. Taken together, CRISPR screens of cis -regulatory elements can define the essential cistrome of a given factor and can inform the development of predictive models of cistrome function.
Competing Interests: The authors declare a competing interest. T.X. and X.S.L. are cofounders and board members of GV20 Oncotherapy. X.S.L. is on the science advisory board (SAB) of 3DMed Care and is a consultant to Genentech. M.B. receives sponsored research support from Novartis. M.B. serves on the SAB of Kronos Bio and as a consultant to H3 Biomedicine. M.B. has served as a consultant to GTx, Inc. and Aleta Biotherapeutics.
(Copyright © 2019 the Author(s). Published by PNAS.)